United Therapeutics Corp (UTHR) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for United Therapeutics Corp, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track UTHR live on Mooboard →

Later5

  • Dec 2026
    United Therapeutics Corp(UTHR)Phase 2/3 readout
    Ralinepag · Phase 3 · PAH; Pulmonary Hypertension
    NCT03683186: A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension. Primary completion 2026-12 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Nov 2027
    United Therapeutics Corp(UTHR)Phase 2/3 readout
    Placebo · Phase 3 · Progressive Pulmonary Fibrosis; Interstitial Lung Disease
    NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF). Primary completion 2027-11 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 2028
    United Therapeutics Corp(UTHR)Phase 2/3 readout
    10 GE Xenokidney · Phase 1 / Phase 2 · ESRD (End-Stage Renal Disease); Kidney Transplantation
    NCT06878560: Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD. Primary completion 2028-10 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 2029
    United Therapeutics Corp(UTHR)Phase 2/3 readout
    GGTA1 KO Thymokidney · Phase 1 / Phase 2 · ESRD (End-Stage Renal Disease); Kidney Transplantation
    NCT07224763: Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD. Primary completion 2029-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2029
    United Therapeutics Corp(UTHR)Phase 2/3 readout
    Inhaled Treprostinil · Phase 3 · Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
    NCT04905693: Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease. Primary completion 2029-12 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗

How United Therapeutics Corp has moved — past-year price reactions

How binary is UTHR? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1%
typical day (1Y)
4
±10% days
46.5%
annualized vol
250
trading days
Largest single-day moves
  • +32.8%2025-09-02no matched headline
  • +13%2026-02-25no matched headline
  • +12.5%2026-03-30no matched headline
  • +10.7%2026-03-09no matched headline
  • +9.6%2025-10-29no matched headline
  • -5.9%2026-02-26no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

United Therapeutics Corp — active clinical pipeline

United Therapeutics Corp's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

5 assets6 programsPh1 0Ph2 2Ph3 3· 1 post-marketing (Ph4)
AreasCardiovascularOther
Inhaled TreprostinilOther
Phase 3
Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis
RalinepagCardiovascular · PTGIR
Phase 3
PAH
10 GE XenokidneyOther
Phase 2
ESRD (End-Stage Renal Disease)
GGTA1 KO ThymokidneyOther
Phase 2
ESRD (End-Stage Renal Disease)

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.